A Study of GC101 TIL in Advanced Breast Cancer (10hospital)

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy (GC 101 TIL) in patients with advanced breast cancer. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Trial Details

NCT ID
NCT05142475
Phase
EARLY_PHASE1
Sponsor
Shanghai Juncell Therapeutics
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Tumor Infiltrating Lymphocytes (TIL)
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Age: 18 years to 75 years;
  • Histologically diagnosed as primary/relapsed/metastasized breast cancer;
  • Expected life-span more than 3 months;
  • Karnofsky≥60% or ECOG score 0-2;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →